Recent developments include a reported Q1 loss, a merger announcement with Fortitude to form a public Zcash mining platform, and multiple buy recommendations from Ascendiant Capital. The company continues to advance its AI-ECG technology and expand commercial engagements.

• HeartSciences reported a net loss for Q1 2027, reflecting ongoing financial challenges [N1][S2].
• In June 2026, HeartSciences announced a merger with Fortitude to form a public Zcash mining platform, with the stock price increasing following the announcement [N2].
• Ascendiant Capital maintained a buy recommendation for HeartSciences in October and December 2025, indicating continued analyst support [N3][N4].
• The company reported fiscal year 2025 financial results highlighting strategic advances in AI-enhanced ECG technology [N5].
• HeartSciences secured a foundational patent for its AI-driven ECG technology in June 2025 [N6].
• The scientific advisory board was expanded with three new appointments to enhance AI-driven cardiac care in May 2025 [N7].
• Quarterly earnings results were reported in March 2025, providing updates on financial performance and AI-ECG innovations [N8].

HeartSciences' cloud-native MyoVista Insights™ platform addresses significant unmet needs in ECG data management and AI integration, potentially expanding the addressable market across diverse healthcare settings. The platform's interoperability and SaaS model align with healthcare IT trends, and the Epic Toolbox designation may facilitate adoption in large health systems. Licensing agreements and a growing AI-ECG marketplace could accelerate algorithm deployment and revenue diversification. The company's strategic focus on platform commercialization and active customer engagements indicate progress toward revenue generation. Foundational patents and scientific advisory board expansions support ongoing innovation.

HeartSciences faces significant risks including ongoing operating losses, liquidity constraints, and a working capital deficit. The FDA clearance for the MyoVista wavECG device remains uncertain, with potential delays or adverse outcomes impacting reputation and prospects. The company depends on successful commercialization of MyoVista Insights™ to generate revenue, but market acceptance, pricing, and reimbursement are uncertain. Material weaknesses in internal controls and Nasdaq listing compliance issues pose additional risks. The company's recent merger into a Zcash mining platform may indicate strategic shifts or diversification that could distract from core healthcare focus.

HeartSciences' competitive strengths lie in its platform-centric approach that simplifies ECG workflows while enabling scalable integration of multiple AI-ECG algorithms. The vendor- and device-agnostic architecture allows interoperability across diverse healthcare IT systems, reducing dependency on any single algorithm or device. The Epic Toolbox designation supports integration within widely used healthcare IT ecosystems. The company's licensing agreements with academic institutions and its AI-ECG marketplace model position it to benefit from broader AI-ECG adoption without bearing full development costs. These factors collectively create barriers to entry and support differentiation in the emerging AI-ECG market.

• Regulatory Approval Risk: The MyoVista wavECG device is under FDA 510(k) review with no assurance of clearance timing or outcome, which could materially affect the company's prospects.
• Financial and Liquidity Risk: The company has incurred significant losses, has a working capital deficit, and low liquidity ratios, indicating challenges in funding operations and growth.
• Market Acceptance and Commercialization Risk: Future revenue depends on market acceptance, pricing, and reimbursement of MyoVista Insights™ and AI-ECG algorithms, which are uncertain.
• Nasdaq Listing Compliance Risk: HeartSciences has received notices for non-compliance with Nasdaq listing requirements, including minimum stockholders' equity, posing risk of delisting.
• Internal Controls Risk: Material weaknesses in internal controls over financial reporting have been identified, which could affect financial accuracy and investor confidence.

• HeartSciences Inc. is a healthcare information technology company focused on advancing electrocardiography (ECG) through artificial intelligence integration.
• The company's primary commercial product is MyoVista Insights™, a cloud-native, vendor- and device-agnostic ECG management platform designed to modernize ECG workflows and enable scalable deployment of AI-ECG capabilities across healthcare systems.
• MyoVista Insights™ is classified as a Medical Device Data System (MDDS) and is exempt from FDA 510(k) requirements.
• The platform supports centralized ECG storage, advanced waveform visualization, workflow optimization, interoperability with electronic medical records and ECG devices, and integration of multiple AI-ECG algorithms within clinical workflows.
• MyoVista Insights™ includes an AI-ECG marketplace hosting algorithms from HeartSciences and third parties, including licensed algorithms from Mount Sinai, such as an aortic stenosis algorithm with FDA Breakthrough Device Designation.
• In March 2026, MyoVista Insights™ received Epic Toolbox designation for the ECG Management System category from Epic Systems Corporation, supporting its positioning within enterprise healthcare IT ecosystems.
• The company has released a significant version upgrade of MyoVista Insights™ in March 2026, adding mobile device access, enhanced reporting, and expanded interoperability for large health systems.
• HeartSciences also developed the MyoVista wavECG device, a 12-lead ECG system designed to complement the platform with embedded AI-ECG algorithms; this device was submitted for FDA 510(k) clearance in December 2025 and remains under review.
• The company has separated FDA submissions for the MyoVista wavECG device and an impaired cardiac relaxation algorithm under development, requiring additional validation due to updated clinical guidelines.
• HeartSciences expects to generate revenue from installation fees, SaaS usage fees, and fees associated with AI-ECG algorithms available through its platform.
• The company has incurred significant operating losses since inception, including a net loss of $3.2 million for the quarter ended July 31, 2026, and had an accumulated deficit of $88.4 million as of that date.
• As of July 31, 2026, HeartSciences had cash and equivalents of $29.9 thousand, current assets of $811.8 thousand, current liabilities of $5.63 million, resulting in a current ratio of 0.14 and a cash ratio of 0.01, indicating liquidity challenges.
• The company has a working capital deficit of $4.8 million as of July 31, 2026.
• HeartSciences is focusing its resources principally on the development and commercialization of the MyoVista Insights™ platform rather than the MyoVista wavECG device, recording a reserve against wavECG inventory in Q1 2027.
• The company faces risks related to FDA clearance timing and outcome for the wavECG device and associated algorithms, which could materially affect its prospects and reputation.
• Heart disease is a leading cause of death globally, with significant unmet needs for early detection; HeartSciences aims to address this through AI-enhanced ECG technology.
• The company believes its platform-centric approach, vendor- and device-agnostic architecture, and AI-ECG orchestration capabilities provide competitive strengths.
• HeartSciences has announced commercial customer engagements and is in active discussions for additional installations of MyoVista Insights™.
• The company has received multiple buy recommendations from Ascendiant Capital in 2025.
• HeartSciences announced a merger with Fortitude to form a public Zcash mining platform in June 2026, indicating diversification or strategic partnership activities.
• The company has expanded its scientific advisory board with new appointments to enhance AI-driven cardiac care.
• HeartSciences has secured foundational patents for its AI-driven ECG technology.
• The company has reported quarterly and fiscal year financial results and strategic advances in AI-enhanced ECG technology in multiple public disclosures.
• Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.